



Midwest Cardiovascular Research Foundation

Fall 2009

Jesse Stoakes Research Award

2009 Stoakes Student Research

Midwest Cardiovascular Research Foundation, Davenport, announced the 2009 recipients of the Jesse Stoakes Student Research Awards for its 8-week summer session.

Jay Welvaert has completed his junior year at Cornell College, Mount Vernon, Iowa, majoring in biochemistry and molecular biology. Jay worked this summer on Bleeding Complications using Angiomax on Carotid Patients.

Raheel Yaseen has completed his junior year at the University of Iowa, Iowa City, majoring in biology in preparation for a medical career. Raheel also worked on Bleeding Complications using Angiomax on Carotid Patients.

The Stoakes Student Research Award was established in 2006 in memory of Jesses Stoakes, son of Penny and David Stoakes of Bettendorf, who had an avid interest in cardiovascular medicine. He died at age 16 of injuries suffered in an automobile accident.

Midwest Cardiovascular Research Foundation was established in 2002 by Nicolas W. Shammass, MD, MS, as a 501(c)(3) non-profit, tax-exempt scientific and educational foundation dedicated to heart health, education and awareness through quality research and professional and community education programs and projects.



In This Issue...	
Jesse Stoakes Research 2009 Award.....	1
Clinical Trials	2, 3
CIPG 2009 Conference.....	4
MCRF Community Lecture.....	5
MCRF Publications	6
MCRF Board of Directors	7
MCRF Donation Form	8

Clinical Trials


Over 24 clinical trials are currently conducted at MCRF. These include peripheral vascular disease, carotid disease, coronary artery disease, congestive heart failure, hypertension, anticoagulants, NSAIDs and others. The following clinical trials are on-going at MCRF:

- ♥ **ABRAXIS:** A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis following Revascularization of the Superficial Femoral Artery (SFA)Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **BIOGEN:** A randomized, double-blind, placebo-controlled, parallel-group, study to assess the effects of intravenous BG9928 on body weight in subjects with acute decompensated heart failure and renal insufficiency....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Quintiles
- ♥ **CG104 (COGENTUS)** (Closed to enrollment): A randomized, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 compared with clopidogrel to reduce upper gastrointestinal events including bleeding and systematic ulcer disease....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Parexel
- ♥ **COSTAR:** (CLOSED) Currently in follow-up stage. Cobalt chromium STent with Antiproliferative for Restenosis II Trial....CLOSED, Direct Stenting will start in February 2007. Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Conor Medsystems
- ♥ **CRESCENDO:** Comprehensive Rimonabant Evaluation Study of Cardiovascular **END**points and **O**utcomes (CRESCENDO).... Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **CHOICE:** Carotid Stenting For **H**igh Surgical Risk Patients; Evaluating **O**utcomes Through The **C**ollection of **C**linical **E**vidence ("CHOICE")....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes RN, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular
- ♥ **REDUCE hf:** Implantable Cardioverter Defibrillator....Principal Investigator: Rafat Padaria, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **CLEARWAY:** Dethrombosis of Lower Extremity Thrombus by Local Delivery of Thrombolysis Using ClearWay Transcatheter Balloon Irrigation: a feasibility and dose finding study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Atrium Medical Corporation
- ♥ **CYPHER ELITE:** A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER@ELITE™ to the CY{HER@BxVELOCITY@ Sirolimus-Eluting Stent Systems....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Johnson & Johnson
- ♥ **DEEP EMBOLI:** (CLOSED) This study is currently in follow-up phase. Distal Embolic Event Protection Using Excimer Laser Ablation in Peripheral Vascular Interventions, a pilot registry....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **EMINENCE:** Evaluation of M118 IN Percutaneous Coronary Intervention. MOM-M118-006 A randomized, multi-center, open-label, parallel group feasibility study to determine the safety and efficacy of the rationally engineered heparin M118 vs. UFH in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI)....Principle Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Momenta Pharmaceuticals, Inc.
- ♥ **PRECISION:** A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen **THIS IS AN ARTHRITIS STUDY**....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Pfizer
- ♥ **PERSEUS** (Closed to enrollment): A **P**rospective **E**valuation in a **R**andomized Trial of the **S**afety and **E**fficacy of the **U**se of the TAXUS® Element™ Paclitaxel-Eluting Coronary **S**tent System for the Treatment of De Novo Coronary Artery Lesions...Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific Corporation


Fall 2009

Clinical Trials - Continued

- ♥ **POLAR CATHETER:** Reduced Stent Utilization with Cryoplasty Using the Ppar Catheter versus Plain Old Balloon Angioplasty: A Randomized Trial....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific, Inc.
- ♥ **ROCHE:** A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular risk in the stable CHD patients, with a documented recent Acute Coronary Syndrome.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Hoffmann-La Roche LTD
- ♥ **SAPPHIRE:** SAPPHIRE WW Stenting And Angioplasty With Protection in Patients at High-Risk For Endarterectomy....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Cordis
- ♥ **ST DETECT:** ST Segment Detection Study....Principal Investigator: Blair Foreman, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **SATURN:** Study of Coronary Atheroma by Intravascular Ultrasound: Effecto of Rosuvastatin Versus AtrovastaiN.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: AstraZeneca
- ♥ **STROLL:** Cordis STROLL Study.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company
- ♥ **TAMARIS:** A randomized, double-blind placebo controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-week intervals on amputation or any death in critical limb ischemia patients with skin lesions....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **TRILOGY:** The TRILOGY ACS Study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Eli Lilly and Company
- ♥ **VIVA II SALVAGE:** (Closed to enrollment.) A ProSepctive, Multi-center TriAL to Evaluate the Safety and Performance of Spectranetics Laser with Adjunct PTA and GORE VIABAHN® Endoprosthesis for the Treatment of SFA Instent Restenosis....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VPI VIVA Physicians Inc.
- ♥ **VIVA I XCELL:** VIVA I: XCELL Trial XPERT™ NITINOL STENTING FOR CRITICALLY ISCHEMIC LOWER LIMBS....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VIVA Physicians, Inc.
- ♥ **ZoMAXX:** (Closed-Currently in follow-up phase.) A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx™ Drug Eluting Coronary Stent System as Compared to TAXUS™ Express²™ Paclitaxel-Eluting Stent in *de novo* Coronary Artery Lesions....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular Devices
- ♥ **BIVALIRUDIN in PPI:** In hospital outcomes of patients receiving PPI with Bivalirudin: Experience from 2 Medical Centers.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Gail Shammass, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company



Pictured Below: Eric J. Dippel, MD
President and Associate Research Director
Midwest Cardiovascular Research Foundation



Pictured Above: Nicolas W. Shammass, MD
Founder and Research Director
Midwest Cardiovascular Research Foundation



Cardiovascular Interventions and Practice Guidelines 2009 Conference

Cardiovascular Interventions and Practice Guidelines (CIPG 2009) is a multidisciplinary conference for general cardiologists, endovascular specialists, primary care providers, cardiovascular nurses, technicians and nurse practitioners jointly sponsored by Midwest Cardiovascular Research Foundation and the Genesis Medical Center. This symposium is designed to give a comprehensive update in various aspects of cardiovascular diseases and focuses on adhering to national guidelines. The invited faculty provided attendees with practical tips useful in daily practice.

This year's conference was held at the Adler Health Education Center, Genesis Heart Institute, Davenport, Iowa, September 11, 2009. Over 175 healthcare professionals benefited from 8 presentations from experts in cardiovascular diseases that included the following speakers:

- ♥ Nicolas W. Shammass, MD, MS (Conference Director)
- ♥ Eric J. Dippel, MD (Conference Director)
- ♥ Blair Foreman, MD (Conference Co-Director)
- ♥ Edmund Coyne, MD
- ♥ Danita Harrison, ARNP
- ♥ Vijay Rajendran, MD
- ♥ Peter Sharis, MD
- ♥ Peter P. Toth, MD, PhD



This conference was made possible through the generous contribution of the following:

Abbott Vascular, Astellas Pharmaceuticals, AstraZeneca Pharmaceuticals, Bard Peripheral Vascular, Bristol-Myers Squibb Company, Boston Scientific, Daiichi Sankyo, Inc.—Lilly USA, Medicine Companies, Medtronic Vascular, Novo Nordisk, Sanofi-Aventis U.S., Inc., Spectranetics, St. Jude Medical, and Takeda Pharmaceuticals.



MCRF Presented at the Illini Heart Club

On August 3, 2009, Dr. Nicolas W. Shammass presented a community lecture to the Illini Heart Group at the Larson Center at Illini Hospital in Illinois. Preventing cardiovascular disease was the focus. Midwest Cardiovascular Research Foundation has given numerous lectures to the community via its staff as part of its mission to disseminate the newest cardiovascular related information to the public in order to improve the quality and prolong the life of people in our community.



MCRF Presented Abstracts in Beijing, China

Beijing, China, October 26, 2009. Dr. Nicolas W. Shammass presented 5 abstracts at the International College of Angiology, 51st Annual Scientific Meeting. These all performed at the Midwest Cardiovascular Research Foundation. The abstracts presented were the following:

1. Predictors of distal embolization in peripheral percutaneous interventions (PPI): data from a real world registry.
2. Predictors of bail out stenting in patients undergoing lower extremity interventions: results from the SMARTHAWK randomized trial.
3. Target lesion revascularization (TLR) and target vessel revascularization (TVR) in patients undergoing angioplasty versus atherectomy: results from the SMARTHAWK trial.
4. Inflammatory and hematologic markers in patients undergoing peripheral angioplasty versus SilverHawk atherectomy: results from the SMARTHAWK randomized trial.
5. In-hospital safety and effectieness of bivalirudin in peripheral percutaneous interventions: data from a real world registry.



Recent Publications Carrying MCRF Name

Shammas NW, Shammas GA, Dippel EJ, Jerin N, Shammas WJ. Predictors of distal embolization in peripheral percutaneous interventions: a report from a large peripheral vascular registry. *J Invasive Cardiol* 2009;21:628-31.

Shammas NW, Shammas GA, Hahn A, Jerin M, Dippel EJ, Winter M. In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center. *Cardiovasc Revasc Med.* 2009;10(3):151-5.

Shammas NW, Shammas G, Bryan D, Rauba J, Dippel EJ, Jerin M. Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions. *J Invasive Cardiol.* 2009;21(6):266-9.

Shammas NW, Shammas GA, Jerin M, Parikh A, Coin K, Dippel EJ, Sharis P, Robken J. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center. *J Invasive Cardiol.* 2009;21(7):321-5.

Shammas NW, Coiner D, Shammas GA, Chirstensen L, Dippel EJ, Jerin M. Distal Embolic Event Protection Using Excimer Laser Ablation in Peripheral Vascular Interventions: Results of the DEEP EMBOLI Registry. *J Endovasc Ther.* 2009;16:197-202.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Derf F, Braunwald E, Harrington RA, Califf RM, Newby LK, EARLY ACS Investigators, (Shammas N listed as one of the subinvestigators). Early versus delayed, provisional eptifibatide in acute coronary syndromes. *N Engl J Med.* 2009;360:2176-90

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators (Shammas NW listed as a collaborator). Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. *Am Heart J.* 2009;158(6):896-901.e3.

Shammas NW, Shammas GA, Dippel EJ, Jerin M. Intraprocedural Outcomes Following distal Lower Extremity Embolization in Patients Undergoing Peripheral Percutaneous Interventions. *Vascular Disease Management*, 2009; 6(3):1-5

Shammas NW. Taking Femoropopliteal Excimer Laser Photoablation Therapy to the Next Level: Defining the Role of the TURBO-Booster Guiding Catheter in the CELLO Registry. *Journal of Endovascular Therapy* 2009;16 676-679.

Shammas NW. Embolic Protection in Percutaneous Intervention. Focus article. Guest Editor. *J Invasive Cardiol* 2009;21 (6): A7-A13

Shammas NW. Optimal Strategy in Lower Extremity Peripheral Percutaneous Interventions: An Interventionalist's Perspective. *Vascular Disease Management* 2009;6:36-40

Shammas NW, Sica DA, Toth PP. A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient. *American Journal of Cardiovascular Drugs*, 2009;9(3):149-162

Shammas NW. Restenosis in Lower Extremity Interventions: Current Status and Future Directions. *J Endovasc Ther* 2009, 16 (Suppl I): I170-182

MCRF Board of Directors

Founder and Research Director Nicolas W. Shammass, MD, MS, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA, and a Clinical Assistant Professor at the University of Iowa in Iowa City. He founded MCRF in 2002 to facilitate cardiovascular clinical research and education. He has been active as principal or co-investigator in over 100 research trials, has been a participating author in over 130 publications, and is a popular presenter at international professional meetings.

President and Associate Research Director Eric J. Dippel, MD, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA. As principal or co-investigator, he is active in peripheral and endovascular research. Dr. Dippel presents his findings through speeches at professional meetings both nationally and internationally, and as an author in industry publications.

Director Clark Arons, CLU, FIC, Bettendorf, IA, is a Senior Financial Consultant with Thrivent Financial for Lutherans, specializing in money management, estate planning and charitable giving. He is active in the community, serves on many boards and is a motivational speaker for young people.

Director John DeDoncker, Bettendorf, IA, is the President of THE National Bank, Bettendorf, IA. As an attorney and banking executive, he shares his expertise on many community organization boards.

Director Blair Foreman, MD, is a cardiologist and electrophysiologist with Cardiovascular Medicine, P.C., Davenport, IA. He actively participates in cardiovascular research projects focusing on electrophysiology.

Director James Kapalis, Bettendorf, IA, is a retired executive of Deere & Company, Moline, IL, and is currently President of Global Supply Chain Solutions, Inc., Bettendorf, IA. He serves as a member of the American Red Cross Disaster Team, and is an active member on many community organization boards.

TO CONTACT MCRF.....

Feel free to contact us regarding submitting manuscripts or articles, obtaining publications, booking a speaker, contributing funds or other matters.

To submit manuscripts, discuss research possibilities, etc., contact:

Dr. Nicolas W. Shammass, MD
Founder & Research Director
Editor-in-Chief, Editorial Board
shammass@mchsi.com

For other assistance or information, contact:

Maureen Koepke
Office Manager
563.324.2828
koepkem@mcrfmd.com



We're On The Web!
www.mcrfmd.com

Midwest Cardiovascular Research Foundation

1622 E. Lombard Street
Davenport, IA 52803

Phone: 563.324.2828
Fax: 563.324.2835

MCRF Donation Form

YES, I want to help support Midwest Cardiovascular Research Foundation research projects and education to promote heart health in this community.

First Name

Last Name

Home Phone

E-mail Address

Home Address

City State Zip

- Senior - \$15
- Family - \$25
- Patron - \$100
- Founder - \$500
- Student - \$15
- Sustainer - \$50
- Benefactor - \$250
- Visionary - \$501+
- Individual - \$20
- My employer will match my gift. I enclose the form for the matching gift.

Checks should be payable to Midwest Cardiovascular Research Foundation

GIFTS are a meaningful way to remember someone special. Your gift will be acknowledged by Midwest Cardiovascular Research Foundation to the person/family remembered.

In honor of _____

In memory of _____

Amount enclosed \$ _____

Please send acknowledgement to:

Name

Address

City, State, ZIP



**Midwest Cardiovascular
Research Foundation**

All gifts to MCRF are fully tax deductible under the U.S. Internal Revenue Code.

100% of all gifts are applied to research and education for heart health in this community.

For more information about MCRF visit www.mcrfmd.com or phone 563.324.2828